Lauryn Robinson loses battle with TWO rare forms of blood cancer

Eight-year-old Lauryn Robinson died at her home in Mold, North Wales, on Sunday, June 29, after a year-long battle with lymphoblastic leukaemia and Burkitts non-Hodgkins lymphoma.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news

Related Links:

354Background: Each year more than 90,000 cases of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) are expected in the US. The standard of care includes immuno-chemotherapy with alkylating agents in combination with an anti-CD20 monoclonal antibody, in addition to targeted therapies such as Bruton’s tyrosine kinase inhibitors. While immuno-chemotherapy regimens are initially effective in inducing responses, most patients inevitably relapse and the same therapies show decreasing efficacy with repeated administration. In recent years, CD37 has emerged as a new therapeutic target for B-cell malignancie...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Oncology, Basic and Translational (Basic Science) III Source Type: research
Discussion In this section, we discuss the mechanisms responsible for lymphomagenesis in the various inborn errors of immunity and provide an overview of the treatment. Defects in Immune Responses That Predispose to Lymphomagenesis in PIDDs The complex immune mechanisms and their interplay that predisposes to neoplastic transformation of B or T cells and development of lymphomas in PIDD patients has not been fully elucidated. However, it is expected that the etiology in most cases is multifactorial and related to a dynamic regulation of immune response and environmental triggers (Figure 3). An underlying intrinsic susce...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
ConclusionThe results of preclinical studies suggest that TAT using 212Pb-NNV003 is a safe and effective method for the treatment of CD37 positive CLL and NHL.DisclosuresSaidi: Orano Med: Employment. Maaland: Nordic Nanovector: Employment. Torgue: Orano Med: Employment, Membership on an entity's Board of Directors or advisory committees. Heyerdahl: Nordic Nanovector: Employment, Equity Ownership. Dahle: Nordic Nanovector ASA: Employment, Equity Ownership, Patents &Royalties.
Source: Blood - Category: Hematology Authors: Tags: 642. CLL: Therapy, excluding Transplantation: Poster III Source Type: research
ConclusionSignificant direct effects for sex and numerous childhood cancer types suggests sex-specific factors such as differences in gene expression from the autosomes or the X chromosome, rather than birthweight, may underlie sex differences in tumor risk.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
Background: Young adult cancer survivors do not respond similarly to the experience of cancer. Thus, we investigated health behavior profiles of young adult cancer survivors and characterize associated sociodemographic and psychosocial characteristics.Methods: A cross-sectional survey assessed sociodemographics, cancer treatment, health behaviors (e.g., alcohol use, tobacco use, physical activity [PA]), healthcare provider interaction, and psychosocial factors for 106 participants from a southeastern cancer center. In-depth semi-structured interviews with a sub-sample of 26 participants were conducted.Results: For the quan...
Source: Cancer Epidemiology Biomarkers and Prevention - Category: Cancer & Oncology Authors: Tags: Prevention Behaviors: Poster Presentations - Proffered Abstracts Source Type: research
Conclusion: Malignancies in HIV positive individual occurred in younger individuals. Non-Hodgkin lymphomas, especially extra-nodal lymphomas, were the most common malignancy. There were no cases of proven Kaposi's sarcoma or invasive cervical carcinomas. There were two cases of multiple myeloma which are infrequently reported.
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
In conclusion, these data demonstrate the potent in vitro and in vivo anti-tumor activity of hLL2-PBD against CD22-positive hematological tumors and warrant further development of this ADC into the clinic.Citation Format: Francesca Zammarchi, David Williams, Karin Havenith, Francois D'Hooge, Philip W. Howard, John A. Hartley, Patrick van Berkel. Preclinical activity of hLL2-PBD, a novel anti-CD22 antibody-pyrrolobenzodiazepine (PBD) conjugate in models of non-Hodgkin lymphoma. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelp...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Experimental and Molecular Therapeutics Source Type: research
BACKGROUND:Burkitt Lymphoma (BL) is the most common histological subtype of childhood and adolescent Non Hodgkin Lymphoma (Cairo et al, Blood 2007; Miles/Cairo, BJH 2012). Pediatric patients with BL with a chromosome 13q deletion, particularly 13q14.3, had significantly poorer outcome and inferior overall survival despite aggressive short, intensive multi-agent chemotherapy (Poirel/Cairo et al, Leukemia 2009; Nelson/Cairo/Sanger et al, BJH 2009). Deleted in Lymphocytic Leukemia 1 (DLEU1) is a BL classifier gene in the 13q14.3 (Dave et al, NEJM 2006) and it has been implicated in regulating programmed cell death in patients...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Molecular and Cellular Biology Source Type: research
Conditions:   Adult Nasal Type Extranodal NK/T-Cell Lymphoma;   Adult Solid Neoplasm;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-Cell Lymphoma;   BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Cutaneous B-Cell Non-Hodgkin Lymphoma;   Estrogen Receptor Negative;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Hepatosplenic T-Cell Lymphoma;   HER2/Neu Negative;   Intraocular Lymphoma;   Lymph...
Source: - Category: Research Source Type: clinical trials
More News: Burkitt Lymphoma | Cancer | Cancer & Oncology | Health | Leukemia | Lymphoma | Non-Hodgkin's Lymphoma